Published in Lancet on November 26, 2005
Effects of Fenofibrate Therapy in Diabetic Nephropathy | NCT03869931
Fenofibrate Intervention as COVID-19 Therapy (FERMIN) | NCT04517396
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Standards of medical care in diabetes--2010. Diabetes Care (2010) 24.28
Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94
Standards of medical care in diabetes--2012. Diabetes Care (2012) 20.66
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Standards of medical care in diabetes--2009. Diabetes Care (2009) 15.78
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65
The metabolic syndrome. Endocr Rev (2008) 5.33
Prevention and early detection of vascular complications of diabetes. BMJ (2006) 4.14
Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol (2006) 4.02
Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab (2009) 3.98
Diabetes in older adults: a consensus report. J Am Geriatr Soc (2012) 3.63
Diabetes in older adults. Diabetes Care (2012) 3.62
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest (2006) 3.48
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Hypertriglyceridemia: its etiology, effects and treatment. CMAJ (2007) 3.42
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise. Arch Intern Med (2012) 2.95
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Use of fibrates in the United States and Canada. JAMA (2011) 2.82
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care (2008) 2.73
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 2.49
Circadian rhythms and metabolic syndrome: from experimental genetics to human disease. Circ Res (2010) 2.49
Insulin resistance and atherosclerosis. J Clin Invest (2006) 2.27
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol (2013) 2.17
Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM (2009) 2.14
Statin use and lower extremity amputation risk in nonelderly diabetic patients. J Vasc Surg (2013) 2.05
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol (2012) 1.95
Update on strategies to increase HDL quantity and function. Nat Rev Cardiol (2009) 1.94
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J (2015) 1.92
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology (2014) 1.89
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet (2009) 1.88
Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review. Nutr J (2014) 1.82
Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol (2009) 1.82
The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol (2008) 1.81
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J (2009) 1.59
Consensus statement on management of dyslipidemia in Indian subjects. Indian Heart J (2014) 1.57
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. Clin Trials (2012) 1.54
Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J (2014) 1.51
Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol (2010) 1.50
Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes (2014) 1.44
PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol (2010) 1.34
The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin (2009) 1.30
PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta (2007) 1.28
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract (2010) 1.24
Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. Health Qual Life Outcomes (2007) 1.22
Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab (2010) 1.22
Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol (2010) 1.22
Partial resistance to peroxisome proliferator-activated receptor-alpha agonists in ZDF rats is associated with defective hepatic mitochondrial metabolism. Diabetes (2008) 1.21
Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol (2011) 1.20
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes Care (2009) 1.19
Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol (2010) 1.19
The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol (2012) 1.17
Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. J Am Soc Nephrol (2014) 1.15
Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care (2012) 1.14
Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol (2010) 1.13
A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants. Environ Health Perspect (2009) 1.13
Metabolic syndrome: the danger signal in atherosclerosis. Vasc Health Risk Manag (2006) 1.13
Impact of diabetes on cardiovascular disease: an update. Int J Hypertens (2013) 1.13
Diabetic retinopathy in sub-Saharan Africa: meeting the challenges of an emerging epidemic. BMC Med (2013) 1.11
Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep (2012) 1.11
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care (2015) 1.10
Patient self-report of prior laser treatment reliably indicates presence of severe diabetic retinopathy. Am J Ophthalmol (2008) 1.10
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol (2012) 1.10
Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol (2010) 1.09
Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol (2006) 1.09
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care (2011) 1.08
Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities. Br J Pharmacol (2012) 1.07
Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes (2015) 1.06
Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol (2010) 1.06
PPAR-α as a key nutritional and environmental sensor for metabolic adaptation. Adv Nutr (2013) 1.04
Mortality rates in trials of subjects with type 2 diabetes. J Am Heart Assoc (2012) 1.04
Diabetes & coronary heart disease: current perspectives. Indian J Med Res (2010) 1.03
Therapeutic impact of leptin on diabetes, diabetic complications, and longevity in insulin-deficient diabetic mice. Diabetes (2011) 1.03
The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer. Cholesterol (2010) 1.03
Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovasc Diabetol (2011) 1.02
Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care (2009) 1.02
The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol (2012) 1.01
Fenofibrate and metabolic syndrome. Endocr Metab Immune Disord Drug Targets (2010) 1.01
Lipid-lowering therapy: who can benefit? Vasc Health Risk Manag (2011) 1.01
Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. J Clin Endocrinol Metab (2011) 1.00
PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans. Am J Physiol Endocrinol Metab (2006) 1.00
Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol (2014) 1.00
Lipid biology of the podocyte--new perspectives offer new opportunities. Nat Rev Nephrol (2014) 0.99
Update on the use of fibrates: focus on bezafibrate. Vasc Health Risk Manag (2008) 0.99
Pediatric triglycerides predict cardiovascular disease events in the fourth to fifth decade of life. Metabolism (2009) 0.99
Racial/ethnic differences in dyslipidemia patterns. Circulation (2013) 0.99
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J (2012) 0.98
In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care (2013) 0.98
Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care (2012) 0.97
Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats. Exp Diabetes Res (2010) 0.97
Use of chronic disease management programs for diabetes: in Alberta's primary care networks. Can Fam Physician (2013) 0.96
Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care (2012) 0.95
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol (2006) 0.95
The sequence of the human genome. Science (2001) 101.55
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med (2001) 56.11
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med (1998) 25.66
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (2012) 17.29
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care (2001) 14.03
Publication bias: the case for an international registry of clinical trials. J Clin Oncol (1986) 12.14
Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ (1997) 9.69
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (2008) 8.53
Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet (2000) 8.46
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet (1998) 8.02
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med (1999) 7.04
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet (2007) 6.82
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke (2001) 6.32
An exploration of the sequence of a 2.9-Mb region of the genome of Drosophila melanogaster: the Adh region. Genetics (1999) 5.87
Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med (1989) 5.79
Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev (2007) 5.63
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J (2005) 5.40
Are antibiotics indicated as initial treatment for children with acute otitis media? A meta-analysis. BMJ (1997) 5.26
Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia (1992) 5.25
Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem (1997) 5.14
Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet (2006) 5.11
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 4.97
A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science (1990) 4.90
General practitioner centred scheme for treatment of opiate dependent drug injectors in Glasgow. BMJ (1997) 4.75
The low molecular weight RNAs of Rous sarcoma virus. I. The 4 S RNA. Virology (1970) 4.64
A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ (1998) 4.44
Patients who reside in common lodging-houses. Br Med J (1966) 4.36
Mapping genes for NIDDM. Design of the Finland-United States Investigation of NIDDM Genetics (FUSION) Study. Diabetes Care (1998) 3.99
Association between dental health and acute myocardial infarction. BMJ (1989) 3.94
Bed rest: a potentially harmful treatment needing more careful evaluation. Lancet (1999) 3.80
Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol (1996) 3.77
Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res (1997) 3.55
Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. Br Med J (Clin Res Ed) (1986) 3.52
Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA (1997) 3.51
The Internet and evidence-based decision-making: a needed synergy for efficient knowledge management in health care. CMAJ (2000) 3.46
Patterns of association with host and habitat: antibody reactive with Sin Nombre virus in small mammals in the major biotic communities of the southwestern United States. Am J Trop Med Hyg (1997) 3.46
Simple, inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicans. J Clin Microbiol (1998) 3.44
Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology (1988) 3.40
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res (1997) 3.38
Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol (1995) 3.38
Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation (2000) 3.12
An analysis of the effects of prospective reimbursement programs on hospital expenditures. Health Care Financ Rev (1981) 3.05
Breast-feeding protects against respiratory syncytial virus infections. Br Med J (1976) 2.98
Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials. JAMA (1996) 2.98
Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev (1987) 2.88
Evidence-based disease management. JAMA (1997) 2.85
Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology (1998) 2.83
The Arabidopsis MALE STERILITY 2 protein shares similarity with reductases in elongation/condensation complexes. Plant J (1997) 2.80
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev (2000) 2.78
Climatic and environmental patterns associated with hantavirus pulmonary syndrome, Four Corners region, United States. Emerg Infect Dis (1999) 2.73
CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell (1993) 2.73
NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes (1994) 2.67
The mitochondrial genotype can influence nuclear gene expression in yeast. Science (1987) 2.62
Prevalence of diabetes and impaired glucose tolerance in the biracial (Melanesian and Indian) population of Fiji: a rural-urban comparison. Am J Epidemiol (1983) 2.60
Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol (1989) 2.57
Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol (1990) 2.56
Blood group M specific haemagglutinin in pyelonephritogenic Escherichia coli. Lancet (1982) 2.56
Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia (1999) 2.51
Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J (2002) 2.49
Pravastatin therapy and the risk of stroke. N Engl J Med (2000) 2.46
How effective are treatments other than antibiotics for acute sore throat? Br J Gen Pract (2000) 2.45
Prevalence of age-associated memory impairment in a randomly selected population from eastern Finland. Neurology (1995) 2.44
Focal therapy for localized prostate cancer: a phase I/II trial. J Urol (2011) 2.43
Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. Am J Trop Med Hyg (1994) 2.42
Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet (2003) 2.37
Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes (1999) 2.36
Estimating an individual's true cholesterol level and response to intervention. JAMA (1991) 2.34
Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes (1996) 2.33
Carotid intima-media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation (1995) 2.24
The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A (1996) 2.24
Diagnostic strategies used in primary care. BMJ (2009) 2.23
Multicenter evaluation of the Cepheid Xpert methicillin-resistant Staphylococcus aureus (MRSA) test as a rapid screening method for detection of MRSA in nares. J Clin Microbiol (2009) 2.20
Social alcohol consumption and low Lp(a) lipoprotein concentrations in middle aged Finnish men: population based study. BMJ (1998) 2.16
Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia (2009) 2.16
Premature dissolution of the microsporocyte callose wall causes male sterility in transgenic tobacco. Plant Cell (1992) 2.15
Measuring social relationships. The Interview Schedule for Social Interaction. Psychol Med (1980) 2.13
Birth of infant after transfer of anucleate donor oocyte cytoplasm into recipient eggs. Lancet (1997) 2.13
Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) (1985) 2.10
Unicondylar knee arthroplasty. J Bone Joint Surg Am (1989) 2.10
Infection control for home health. Infect Control Hosp Epidemiol (1990) 2.09
The low molecular weight RNAs of Rous sarcoma virus. II. The 7 S RNA. Virology (1970) 2.08
Is the timing of post-vasectomy seminal analysis important? Br J Urol (1998) 2.08
Rapid detection of Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) in wound specimens and blood cultures: multicenter preclinical evaluation of the Cepheid Xpert MRSA/SA skin and soft tissue and blood culture assays. J Clin Microbiol (2009) 2.07
Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol (1994) 2.06
Barriers to breast and cervical cancer screening among Vietnamese-American women. Am J Prev Med (1997) 2.05
Synthesis of a deoxyribonucleic acid sequence complementary to ovalbumin messenger ribonucleic acid and quantification of ovalbumin genes. J Biol Chem (1973) 2.05
Corporeal plication for surgical correction of Peyronie's disease. J Urol (1990) 2.03
Training in general (internal) medicine alone. Clin Med (2001) 2.03